
Paul Friedman
Articles
-
2 months ago |
nature.com | Demilade Adedinsewo |Bosede Afolabi |Oyewole A. Kushimo |Kehinde F. Ibiyemi |Hadijat Olaide Raji |Sadiq H. Ringim | +9 more
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03243-9, published online 2 September 2024. In the version of this article initially published, the Acknowledgements did not include thanks to the Dalio Philanthropies. The error has been corrected in the HTML and PDF versions of the article.
-
Nov 8, 2024 |
healio.com | Scott Buzby |Richard Smith |Paul Friedman |Patricia A. Pellikka
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Solicitation of clinician input during AI tool development often happens late stage, if at all.
-
Nov 6, 2024 |
healio.com | Scott Buzby |Richard Smith |Paul Friedman |Dipti Itchhaporia
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Implementation science remains the largest challenges to widespread use of AI in medicine. Considerations for data security, patient preference for data sharing and regulatory labeling are key.
-
Nov 4, 2024 |
healio.com | Scott Buzby |Richard Smith |Patricia A. Pellikka |Paul Friedman
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Guidance is emerging on the use of AI to improve CVD outcomes. AI has demonstrated potential in areas such as imaging and ECG interpretation, but outcomes data and interpretability are lacking.
-
Sep 2, 2024 |
nature.com | Demilade Adedinsewo |Bosede Afolabi |Oyewole A. Kushimo |Kehinde F. Ibiyemi |Hadijat Olaide Raji |Sadiq H. Ringim | +9 more
AbstractNigeria has the highest reported incidence of peripartum cardiomyopathy worldwide. This open-label, pragmatic clinical trial randomized pregnant and postpartum women to usual care or artificial intelligence (AI)-guided screening to assess its impact on the diagnosis left ventricular systolic dysfunction (LVSD) in the perinatal period.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →